Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Penumbra (PEN) Posts Earnings in Q4, Revenues Top Estimates

Penumbra (PEN) sees strong growth across all geographical regions and product lines in Q4.

    Integra LifeSciences (IART) Beats on Q4 Earnings & Revenues

    Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.

      Medtronic (MDT) Expands in the U.S. with 2.0mm DES Launch

      Medtronic (MDT) consistently focuses on boosting CSH segment.

        NuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 View

        NuVasive (NUVA) gains on continued growth in international business in Q4.

          PetMed (PET) Focuses on Advertising to Boost New Order Sales

          PetMed (PETS) implements several strategies to revitalize top line.

            STERIS Focuses on Expanding Core Business, Competition Rife

            STERIS (STE) pursues six acquisitions in the first nine months of fiscal 2018.

              PerkinElmer (PKI) Down 6.9% Since Earnings Report: Can It Rebound?

              PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Cardinal Health Strong on Medical & Pharmaceutical Segments

                Cardinal Health (CAH) gains large number of Pharmaceutical Distribution customers.

                  Here's Why You Should Invest in LabCorp (LH) Stock Right Now

                  Strong guidance and Covance Drug Development's sturdy growth raise investors optimism on LabCorp (LH).

                    Medtronic (MDT) Unveils MiniMed Mio Advance Infusion Set

                    Medtronic (MDT) continues to adopt initiatives to drive the performance of its Diabetes segment.

                      Integer Holdings (ITGR) Beats on Q4 Earnings, Issues '18 View

                      Integer Holdings' (ITGR) fourth-quarter 2017 results benefit from strong performance in its Medical and Non-Medical units.

                        5 Reasons Why You Should Add Becton, Dickinson (BDX) Now

                        Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.

                          Here's Why You Should Keep Omnicell (OMCL) in Your Portfolio

                          Omnicell (OMCL) continues to progress well with its three-legged strategy. However, escalating costs and tough hospital spending trends pose threats.

                            Here's Why You Should Invest in Edwards Lifesciences (EW) Now

                            Recent buyouts and CE Mark boost investors' confidence in Edwards Lifesciences (EW).

                              Ecolab (ECL) Misses Q4 Earnings Estimates, View Impressive

                              Despite strength in Global Industrial and Global Institutional segments, Ecolab (ECL) ended the fourth quarter on an unfavorable note.

                                Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat

                                Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.

                                  Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                                  IDEXX Laboratories (IDXX) continues to boost investor confidence on strong companion animal business along with growth across all segments.

                                    Medtronic (MDT) Beats on Q3 Earnings, Reiterates FY18 View

                                    Medtronic (MDT) rides high on strength in all business segments in Q3.

                                      Myriad Genetics Banks on Product Launches, Competition Rife

                                      Myriad Genetics (MYGN) focuses on strengthening the Molecular Diagnostics portfolio through product launches.

                                        Abiomed Hits New 52-Week High: 4 Factors Driving the Stock

                                        Abiomed's (ABMD) recent regulatory approvals and raised guidance boost investors' confidence.

                                          Edwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm

                                          Edward Lifesciences (EW) witnesses multiple developments in THV segment.

                                            Medtronic's Positive Study Results May Expand Customer Base

                                            Medtronic (MDT) leaves no stone unturned to boost the performance of its Diabetes business.

                                              Cardiovascular Systems Portfolio Solid, Competition Rife

                                              Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.

                                                Allscripts (MDRX) Q4 Earnings Meet, Revenues Beat Estimates

                                                Solid year-over-year growth in Client Services revenues drove Allscripts in Q4.

                                                  Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View

                                                  Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.